Inmune Bio Stock Price Prediction

INMB Stock  USD 10.62  0.48  4.73%   
At the present time, the RSI of INmune Bio's share price is approaching 43. This usually indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling INmune Bio, making its price go up or down.

Oversold Vs Overbought

43

 
Oversold
 
Overbought
INmune Bio stock price prediction is an act of determining the future value of INmune Bio shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation. The successful prediction of INmune Bio's future price could yield a significant profit. Please, note that this module is not intended to be used solely to calculate an intrinsic value of INmune Bio and does not consider all of the tangible or intangible factors available from INmune Bio's fundamental data. We analyze noise-free headlines and recent hype associated with INmune Bio, which may create opportunities for some arbitrage if properly timed.
Below are the key fundamental drivers impacting INmune Bio's stock price prediction:
EPS Estimate Next Quarter
(0.58)
EPS Estimate Current Year
(2.19)
EPS Estimate Next Year
(1.95)
Wall Street Target Price
19.67
EPS Estimate Current Quarter
(0.44)
It is a matter of debate whether stock price prediction based on information in financial news can generate a strong buy or sell signal. We use our internally-built news screening methodology to estimate the value of INmune Bio based on different types of headlines from major news networks to social media. The INmune stock price prediction module provides an analysis of price elasticity to changes in media outlook on INmune Bio over a specific investment horizon. Using INmune Bio hype-based prediction, you can estimate the value of INmune Bio from the perspective of INmune Bio response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards INmune Bio using INmune Bio's stock options and short interest. It helps to benchmark the overall future attitude of investors towards INmune using crowd psychology based on the activity and movement of INmune Bio's stock price.

INmune Bio Implied Volatility

    
  70.37  
INmune Bio's implied volatility exposes the market's sentiment of INmune Bio stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if INmune Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that INmune Bio stock will not fluctuate a lot when INmune Bio's options are near their expiration.
This module is based on analyzing investor sentiment around taking a position in INmune Bio. This speculative approach is based exclusively on the idea that markets are driven by emotions such as investor fear and greed. The fear of missing out, i.e., FOMO, can cause potential investors in INmune Bio to buy its stock at a price that has no basis in reality. In that case, they are not buying INmune because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

INmune Bio after-hype prediction price

    
  USD 10.09  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out INmune Bio Basic Forecasting Models to cross-verify your projections.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of INmune Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intrinsic
Valuation
LowRealHigh
7.2813.0918.90
Details
Naive
Forecast
LowNextHigh
3.769.5715.38
Details
3 Analysts
Consensus
LowTargetHigh
15.7717.3319.24
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.57-0.54-0.52
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as INmune Bio. Your research has to be compared to or analyzed against INmune Bio's peers to derive any actionable benefits. When done correctly, INmune Bio's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in INmune Bio.

INmune Bio After-Hype Price Prediction Density Analysis

As far as predicting the price of INmune Bio at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in INmune Bio or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of INmune Bio, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

INmune Bio Estimiated After-Hype Price Volatility

In the context of predicting INmune Bio's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on INmune Bio's historical news coverage. INmune Bio's after-hype downside and upside margins for the prediction period are 4.28 and 15.90, respectively. We have considered INmune Bio's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
10.62
10.09
After-hype Price
15.90
Upside
INmune Bio is slightly risky at this time. Analysis and calculation of next after-hype price of INmune Bio is based on 3 months time horizon.

INmune Bio Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as INmune Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading INmune Bio backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with INmune Bio, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.08 
5.81
  0.05 
  0.01 
7 Events / Month
12 Events / Month
In about 7 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
10.62
10.09
0.49 
1,002  
Notes

INmune Bio Hype Timeline

INmune Bio is currently traded for 10.62. The entity has historical hype elasticity of -0.05, and average elasticity to hype of competition of -0.01. INmune is expected to decline in value after the next headline, with the price expected to drop to 10.09. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.49%, whereas the daily expected return is currently at -0.08%. The volatility of related hype on INmune Bio is about 7539.69%, with the expected price after the next announcement by competition of 10.61. About 35.0% of the company shares are held by company insiders. The book value of INmune Bio was currently reported as 2.08. The company recorded a loss per share of 1.67. INmune Bio had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be in about 7 days.
Check out INmune Bio Basic Forecasting Models to cross-verify your projections.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

INmune Bio Related Hype Analysis

Having access to credible news sources related to INmune Bio's direct competition is more important than ever and may enhance your ability to predict INmune Bio's future price movements. Getting to know how INmune Bio's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how INmune Bio may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
TFFPTff Pharmaceuticals(0.48)9 per month 0.00 (0.06) 15.12 (10.88) 56.27 
ANEBAnebulo Pharmaceuticals(0.05)5 per month 3.50  0.04  6.20 (5.51) 20.75 
ABCMAbcamPLC(0.02)11 per month 0.15 (0.03) 1.22 (0.57) 3.77 
ANTXAN2 Therapeutics(0.05)8 per month 0.00 (0.21) 3.78 (9.57) 77.96 
CUECue Biopharma(0.03)8 per month 0.00 (0.16) 9.44 (6.86) 30.04 
ANIXAnixa Biosciences(0.04)6 per month 0.00 (0.18) 5.83 (5.57) 26.45 
INABIn8bioInc 0.07 5 per month 0.00 (0.08) 7.89 (7.20) 21.37 
PYPDPolyPid(0.03)5 per month 0.00 (0.10) 8.58 (9.44) 28.92 
AVTEAerovate Therapeutics 0.32 8 per month 4.93  0.05  11.11 (6.86) 28.53 
ELYMEliem Therapeutics(0.12)7 per month 3.04  0.07  4.17 (6.23) 79.43 
DBTXDecibel Therapeutics 0.08 8 per month 3.20  0.06  6.35 (7.45) 83.15 
AVXLAnavex Life Sciences(0.13)6 per month 0.00 (0.18) 6.64 (6.83) 18.65 
SAVACassava Sciences 0.03 8 per month 0.00 (0.09) 7.35 (7.31) 25.72 
BIVIBiovie Inc(0.02)4 per month 0.00 (0.1) 6.38 (9.64) 95.81 
CGTXCognition Therapeutics(0.04)10 per month 0.00 (0.06) 7.65 (6.19) 16.60 
TCRXTscan Therapeutics(0.79)7 per month 3.64  0.1  7.88 (6.21) 28.23 
DRMADermata Therapeutics(0.01)4 per month 0.00 (0.03) 9.38 (6.12) 39.87 

INmune Bio Additional Predictive Modules

Most predictive techniques to examine INmune price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for INmune using various technical indicators. When you analyze INmune charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About INmune Bio Predictive Indicators

The successful prediction of INmune Bio stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as INmune Bio, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of INmune Bio based on analysis of INmune Bio hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to INmune Bio's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to INmune Bio's related companies.
 2021 2022 2023 2024 (projected)
Graham Number14.5110.988.925.75
Receivables Turnover0.03290.04420.06350.0603

Story Coverage note for INmune Bio

The number of cover stories for INmune Bio depends on current market conditions and INmune Bio's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that INmune Bio is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about INmune Bio's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

INmune Bio Short Properties

INmune Bio's future price predictability will typically decrease when INmune Bio's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of INmune Bio often depends not only on the future outlook of the potential INmune Bio's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. INmune Bio's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding18 M
Cash And Short Term Investments35.8 M
When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:
Check out INmune Bio Basic Forecasting Models to cross-verify your projections.
For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.67)
Revenue Per Share
0.009
Quarterly Revenue Growth
(0.71)
Return On Assets
(0.27)
Return On Equity
(0.61)
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.